Citation

Fenton C, Lee A. Drug. Ther. Persp. 2022; 38(7): 316-321.

Copyright

(Copyright © 2022)

DOI

10.1007/s40267-022-00921-x

PMID

unavailable

Abstract

CNS stimulants used in the management of attention-deficit/hyperactivity disorder (ADHD) may suppress appetite, and thus growth. In randomised clinical trials, CNS stimulants demonstrated growth suppression in patients, with some trials demonstrating a dose-dependent effect. Weight deficits were attenuated in adolescence, however, deficits in height were carried into adulthood. Taking CNS stimulants with or after meals, initiating treatment at an older age or using drug holidays may improve appetite and growth. The benefits achieved with these strategies must be balanced against the risks of ineffectively managed ADHD. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Language: en

Keywords

human; suicide; abdominal pain; headache; patient referral; sleep disorder; medical specialist; amphetamine derivative; side effect; methylphenidate; growth retardation; dexamphetamine; central stimulant agent; body mass; growth inhibition; atomoxetine; Article; body height; diet supplementation; guanfacine; lisdexamfetamine; cognitive behavioral therapy; loss of appetite; elevated blood pressure; risk behavior; attention deficit hyperactivity disorder; body weight loss; psychological care; clinical monitoring